Carey Hobbs

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

A. Armstrong, D. George, E. Yu, 2017, European journal of cancer.

Development of a Novel c-MET–Based CTC Detection Platform

M. Garcia-Blanco, M. Harrison, A. Armstrong, 2016, Molecular Cancer Research.

Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).

A. Armstrong, D. George, E. Yu, 2015 .